Status:
RECRUITING
The China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The CHAPERONE Study
Lead Sponsor:
Shanghai Zhongshan Hospital
Conditions:
Multiple Myeloma
Monoclonal Gammopathy of Undetermined Significance
Eligibility:
All Genders
18+ years
Brief Summary
The goal of the China Monoclonal Gammopathy Screening Project in First-degree Relatives of Patients With Multiple Myeloma (CHAPERONE) study is to assess the clinical significance of screening for mono...
Detailed Description
The CHAPERONE study aims to assess the clinical significance of screening for monoclonal gammopathy in first-degree relatives of patients with multiple myeloma in China. The main objectives it aims t...
Eligibility Criteria
Inclusion
- Male or female over the age of 18;
- First-degree relatives (including parents, children, and biological siblings) have multiple myeloma diagnosed by the International Myeloma Working Group (IMWG) Myeloma Diagnostic Criteria;
- Understand the purpose and procedure of this trial and voluntarily participate in this screening study;
- Participants should be willing and able to follow the study follow-up plan and other protocol requirements.
Exclusion
- Patients with a known diagnosis of plasma cell diseases, such as MGUS, smoldering myeloma (SMM), or multiple myeloma
Key Trial Info
Start Date :
July 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2035
Estimated Enrollment :
10000 Patients enrolled
Trial Details
Trial ID
NCT05965115
Start Date
July 1 2023
End Date
August 1 2035
Last Update
August 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongshan Hospital，Fudan University
Shanghai, Shanghai Municipality, China, 200032